Castleark Management LLC Invests $6 Million in Krystal Biotech, Inc. $KRYS

Castleark Management LLC bought a new stake in Krystal Biotech, Inc. (NASDAQ:KRYS - Free Report) during the second quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The firm bought 16,150 shares of the company's stock, valued at approximately $6,002,000. Castleark Management LLC owned 0.05% of Krystal Biotech at the end of the most recent quarter.

Other hedge funds and other institutional investors have also made changes to their positions in the company. Silvant Capital Management LLC purchased a new stake in Krystal Biotech during the 2nd quarter worth $30,000. Western Wealth Management LLC purchased a new position in Krystal Biotech in the first quarter valued at about $34,000. Greenline Wealth Management LLC acquired a new position in shares of Krystal Biotech during the fourth quarter worth about $34,000. Danske Bank A S acquired a new position in shares of Krystal Biotech during the third quarter worth about $35,000. Finally, UMB Bank n.a. boosted its position in shares of Krystal Biotech by 34.6% in the fourth quarter. UMB Bank n.a. now owns 144 shares of the company's stock worth $36,000 after buying an additional 37 shares during the period. Institutional investors and hedge funds own 86.29% of the company's stock.

Insider Activity at Krystal Biotech

In other Krystal Biotech news, Director Dino A. Rossi sold 25,000 shares of the company's stock in a transaction on Friday, August 14th. The stock was sold at an average price of $329.12, for a total value of $8,228,000.00. Following the transaction, the director owned 50,000 shares of the company's stock, valued at approximately $16,456,000. This represents a 33.33% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, EVP John Charles Thomas sold 1,000 shares of the business's stock in a transaction dated Thursday, June 25th. The stock was sold at an average price of $347.27, for a total value of $347,270.00. Following the sale, the executive vice president owned 1,000 shares in the company, valued at approximately $347,270. The trade was a 50.00% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold 51,000 shares of company stock worth $16,278,020 in the last 90 days. Corporate insiders own 13.10% of the company's stock.

Krystal Biotech Stock Up 4.2%

Shares of Krystal Biotech stock opened at $356.19 on Wednesday. The business has a 50-day moving average price of $348.02 and a 200 day moving average price of $302.59. Krystal Biotech, Inc. has a fifty-two week low of $136.73 and a fifty-two week high of $382.54. The firm has a market cap of $10.54 billion, a P/E ratio of 44.64 and a beta of 0.53.

Krystal Biotech (NASDAQ:KRYS - Get Free Report) last posted its quarterly earnings results on Monday, August 3rd. The company reported $1.79 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $1.70 by $0.09. The company had revenue of $119.22 million for the quarter, compared to the consensus estimate of $120.93 million. Krystal Biotech had a net margin of 54.82% and a return on equity of 19.34%. As a group, equities research analysts anticipate that Krystal Biotech, Inc. will post 7.68 earnings per share for the current year.

Wall Street Analyst Weigh In

KRYS has been the subject of a number of recent research reports. TD Cowen increased their target price on Krystal Biotech from $306.00 to $403.00 and gave the company a "buy" rating in a research note on Thursday, June 18th. Citigroup upped their price target on Krystal Biotech from $378.00 to $386.00 and gave the stock a "buy" rating in a report on Tuesday, August 4th. Wall Street Zen downgraded shares of Krystal Biotech from a "buy" rating to a "hold" rating in a research report on Saturday, June 20th. Evercore reissued an "outperform" rating and set a $300.00 target price on shares of Krystal Biotech in a research report on Tuesday, May 5th. Finally, Bank of America raised their price target on shares of Krystal Biotech from $364.00 to $396.00 and gave the company a "buy" rating in a report on Tuesday, July 14th. One research analyst has rated the stock with a Strong Buy rating, ten have issued a Buy rating and two have assigned a Hold rating to the stock. Based on data from MarketBeat.com, the stock currently has an average rating of "Moderate Buy" and a consensus target price of $365.40.

Krystal Biotech Profile

Krystal Biotech, Inc is a clinical-stage biotechnology company focused on developing gene therapies for rare dermatological diseases. Headquartered in Pittsburgh, Pennsylvania, the company applies proprietary viral vector delivery technology to enable topical administration of corrective genes directly to the skin. By targeting the underlying genetic causes of inherited skin disorders, Krystal Biotech seeks to address areas of high unmet medical need with potentially transformative treatments.

The company's lead product candidate, KB103, is designed to deliver a functional COL7A1 gene to patients with dystrophic epidermolysis bullosa (DEB), a severe and often debilitating blistering condition.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source